Catalent, Inc. (NYSE:CTLT) Holdings Lifted by American Century Companies Inc.

American Century Companies Inc. grew its position in Catalent, Inc. (NYSE:CTLT) by 14.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 41,069 shares of the company’s stock after purchasing an additional 5,298 shares during the period. American Century Companies Inc.’s holdings in Catalent were worth $2,309,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of CTLT. Gamco Investors INC. ET AL boosted its holdings in shares of Catalent by 403.3% in the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after acquiring an additional 20,273 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Catalent by 2,792.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after purchasing an additional 498,540 shares during the last quarter. UniSuper Management Pty Ltd lifted its stake in Catalent by 509.4% during the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock valued at $1,028,000 after purchasing an additional 15,217 shares during the last quarter. Swedbank AB acquired a new stake in Catalent during the first quarter valued at approximately $1,659,000. Finally, SG Americas Securities LLC lifted its stake in Catalent by 147.4% during the first quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock valued at $5,622,000 after purchasing an additional 59,339 shares during the last quarter.

Catalent Trading Up 0.1 %

CTLT opened at $60.33 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The company has a market cap of $10.92 billion, a price-to-earnings ratio of -9.89, a price-to-earnings-growth ratio of 2.32 and a beta of 1.15. The firm has a 50 day simple moving average of $59.69 and a 200 day simple moving average of $57.33. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, sell-side analysts anticipate that Catalent, Inc. will post 0.85 earnings per share for the current year.

Insider Buying and Selling

In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares in the company, valued at $1,921,840.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,403 shares of company stock worth $902,503. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CTLT has been the subject of several research analyst reports. Barclays upped their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, StockNews.com began coverage on shares of Catalent in a research report on Thursday. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.